DOCSLIB.ORG

Entamoeba Histolytica/E. Dispar

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Entamoeba Histolytica/E. Dispar Entamoeba histolytica/E. dispar A. Haghighi, Tuesday, March 05, 2019 Classification of Protozoa ? • The protozoa are generally unicellular and may be divided for convenience, into four distinct ﺣﺮﮐﺖ :groups based on method of locomotion 1. Mastigophora (Flagella)/Metamonada 2. Sarcodina (Pseudophora)/ Amoebazoa 3. Apicomplexa (microtubule complex) 4. Ciliophora (Ciliates) Human species of Amoebae The important intestinal amoeba in human Phylum: Sarcomastigophora / Amoebazoa Genus: 1- Entamoeba Species: - Entamoeba histolytica - Entamoeba dispar - Entamoeba moshkovskii - Entamoeba coli - Entaomeba hartmanni - Entamoeba gingivalis Genus: 2- Endolimax Species: Endolimax nana Genus: 3- Iodamoeba Species: Iodamoeba butschlii Classification based on number of nuclei in the mature cyst: 1. Octonucleate cyst group: - E. coli 2. Quadrinucleate cyst group: - E. histolytica - E. dispar - E. hartmanni - E. moshkovskii - Endolimax nana 3. Uninucleate cyst group: - Iodamoeba buetschlii 4. No cyst - E. gingivalis General characteristics of amoebas 1- Active form (Trophozoite) has no cell wall 2- The cytoplasm of active form consists of two parts, Ectoplasm and Endoplasmic 3- Movement is performed by forming a pseudopod in the active form Amoeba = Variable 4- There is no particular way to get food (No mouth) 5- They do not have a fixed shape, because they create pseudopod for locomotion and to get food. 6- They are Anaerobic, Therefore, Lack of mitochondria, endoplasmic network and Golgi apparatus. (New molecular findings suggest traces of these organelles) Entamoeba histolytica << HISTORY>> • 1875 Fedor Aleksandrovich Losch Amoeba coli • 1903 Fritz Schaudinn Entamoeba histolytica • 1925 Emile Brumpt E. dysenteriae (Craig 1905) E. dispar (= different) • 1912 Von Prowazek E. dispar (= different) Small Race (E. hartmanni) • 1957, 1959 Burrows • 1973 Martinez-Palomo Two species? E. histolytica pathogen • 1978-1988 Peter Sargeant and … E. histolytica nonpathogen E. histolytica • 1993 Louis Diamond & C.G. Clark E. dispar • 1997 WHO meeting in Mexicocity E. histolytica E. histolytica/E. disbar prevalence (Schoudinn 1903/ Brumt 1925) 20 to 30% in the tropics area And 5% 10% of world population in temperature (about 500-700 millions) climate nations 10% E. histolytica 90% E. dispar (50-70,000,000) (450-650,000,000) <Non pathogen> Therefore Only 1% of world population Infected with E. histolytica No (Amebiasis) Treatment 5-10% 90-95% About 10% 45-65,000,000 (5-7,000,000) (700,000) asymptomatic Extra intestinal With symptoms Cyst passers Amebiasis 5-7,000,000 About 90% 45 - 65,000,000 Intestinal and Extra intestinal Cyst passers ? (4.500,000-6.500,000) Amebiasis Intestinal amebiasis Great geographical virulence and symptomes in the world, ranging from 1% in Greece to 21% in Egypt, average 10% of infected patients) * Up to 100,000 deaths, second after malaria in protozoan parasites Transmission routes Feces (Person to person by the oro-fecal route) .1 Agent of transmission Finger .2 Food .3 Trophozoit Cyst Fluid (Water) .4 Flies .5 E. histolytica and E. dispar << Morphology and life cycle>> (10-20m) Ch. body Nucleus Trophozoite Oral infection Brain Cell wall Karyosome Metacystic development Cyst Lung Encystation Clumps of glycogen Galactose/N-acetylgalactoseamine (Gal/GalNAc) lectin protein Large intestine Endoplasm Ectoplasm Liver Trophozoite (Haematophge) 15-60 m Pathogenicity A- (Intestinal diseases) or << Intestinal amoebiasis>> B- (Extraintestinal diseases) << Extraintestinal amoebiasis>> Intestinal amoebiasis ? Frequently: - Anti-amoebic Ab is + - and Stool Ag test is + • Asymptomatic infection Diarrhea, Dysentery, weight • Symptomatic noninvasive infection loss, fever, tenterness, Heme + • Acute rectocolitis (dysentery) • Fulminant colitis with perforation • Ameboma • Chronic nondysenteric colitis • Perianal ulceration Flask form ulcers Familiarity with these diverse manifestations and epidemiologic risk factors greatly facilitates A rapid , correct diagnosis Extraintestinal amoebiasis ? • Amoebic Liver Abscess (ALA) Brain • Lung abscess • Brain abscess Lung • Splenic abscess • Subdiaphragmatic • .Large intestine ab • Amebiasis cutis Liver • Genitourinary abscess Diagnosis methods • Intesinal amoebiasis • Extraintestinal amoebiasis Based on : 1- Doctor: Pay attention to clinical findings, geographical location, history of illness and findings Epidemiologic 2- Parasitological methods: Detection of trophozoite or cysts in feces or abscesses by: - Wet mount stool exam - Stool concentration (Formalin-ether technique) (Three alternate stool tests are recommended) . Cultivation Staining 3. Serologically tests: * IFA * ELISA (Sensitive tests) * IHA * CIE or GD : Non sensitive for acute diseases * Antigen capture (TechLab) 4. Bichemical or Biological methods: -PCR - Zymoden analysis Diagnosis of amebic liver abscess Cinical symptoms Lesion in the liver Positive amebic serology ***** Medical recommendation for diagnosis and treatment WHO News and activities Bulletin of the WHO, 1997, 75 (3); 291-292 When diagnosis is made by light microscopy, the cysts of two species (10-20 um in diameter) are indistinguishable and should be reported as: E. histolytica/E. dispar Trophozoites with ingested red blood cells in fresh stool or other specimens and trophozoites in tissue biopsies are both strongly correlated with the presence of E. histolytica and invasive disease. In symptyomatic individuals the presence of high titers of specific antibody is also strongly correlated with invasive amoebiasis. Optimally, E. histolytica should be specifically identified, and infections, if present, treated is recommended. If only E. dispar is identified, no treatment is necessary. If the infected individual has gastrointestinal symptoms, other causes should be sought. If E. histolytica/E. dispar has been detected in symptomatic patients, it should not be assumed that E. histolytica is the cause of symptoms and other explanations should also be considered. Treatment • There are two classes of antiamoebic drugs: a) Tissue amoebicies (Such as 5-nitoimidazole; e.g. Metronidazole) b) and luminal amoebicides (such as diloxanide furoate and paromomaycine). Invasive disease should be treated with a tissue amoebiside followed by a luminal amoebicide. Tissue amoebicides are not appropriate for treatment of asymptomatic individuals, unless there is other evidence for invasive amoebiasis. • Chemoprophylaxis is never appropriate. 24 Treatment Luminal agents : Diloxanide furoate A: In E. histolytica cyst passers Paromomycine (Asymptomatic intestinal colonization) Iodoquinol B: Invasive rectocolitis Tissue agents : Bowel wall only (Amoebic colitis) - Tetracycline -Erythromycine C- Extraintesinal diseases All tissues -Metronidazile (Amoebic liver abscess) -Tinidazole -Emetine hydrochloride -Dehydroemetine A: In E. histolytica cyst passers 1. Diloxanid foroate - 500 mg orally 3 times a day for 10 days 2 . Paromomycine - 30 mg/kg/days in 3 divided doses for 5-10 days 3. Tetracycline - 250 mg qid for 10 days then Iodoquinol, 650 mg tid for 20 days 4. Metronidazol - 750 mg tid for 10 days. B: Invasive rectocolitis 1. Metronidasol 2. Tetracycline, 3. Dehydroemetine C- Extraintesinalis treatment 1. Metronidasol 2. Tinidazol 3. Dehydroemetine Treatment should be follow with one of the effective medicines on the cyst Prevention 1- Individual health (hand wash with soap, Destroying the flies and cockroaches, Using healthy food and especially vegetables) 2- Public Health (Proper disposal of waste, Environmental improvement, Health improvement, Proper disposal of sewage) 3- Health Education (Use of Mothers' Breastfeeds, Health Education in Schools, Health education through radio and television) Vaccination: Researching on 3 genes .
Load more

Recommended publications
  • Index Vol. 12-15
    353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in­ 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Cutaneous Amebiasis in Pediatrics
    OBSERVATION Cutaneous Amebiasis in Pediatrics Mario L. Magan˜a, MD; Jorge Ferna´ndez-Dı´ez, MD; Mario Magan˜a,MD Background: Cutaneous amebiasis (CA), which is still Conclusions: Cutaneous amebiasis always presents with a health problem in developing countries, is important painful ulcers. The ulcers are laden with amebae, which to diagnose based on its clinical and histopathologic are relatively easy to see microscopically with routine features. stains. Erythrophagocytosis is an unequivocal sign of CA. Amebae reach the skin via 2 mechanisms: direct and in- Observations: Retrospective medical record review of direct. Amebae are able to reach the skin if there is a lac- 26 patients with CA (22 adults and 4 children) treated from eration (port of entry) and if conditions in the patient 1955 to 2005 was performed. In addition to the age and are favorable. Amebae are able to destroy tissues by means sex of the patients, the case presentation, associated ill- of their physical activity, phagocytosis, enzymes, secre- ness or factors, and method of establishing the diagnosis, tagogues, and other molecules. clinical pictures and microscopic slides were also analyzed. Arch Dermatol. 2008;144(10):1369-1372 UTANEOUS AMEBIASIS (CA) ria, are opportunistic organisms that act as can be defined as damage pathogens, usually in the immunocompro- to the skin and underly- mised host, who can develop disease in any ing soft tissues by tropho- organ, such as the skin and central ner- zoites of Entamoeba histo- vous system. This kind of amebiasis has be- lytica, the only pathogenic form for humans. come more common during the last few C 8-18 Cutaneous amebiasis may be the only ex- years.
    [Show full text]
  • International Journal for Scientific Research & Development| Vol. 4, Issue 09, 2016 | ISSN (Online): 2321-0613
    IJSRD - International Journal for Scientific Research & Development| Vol. 4, Issue 09, 2016 | ISSN (online): 2321-0613 Study of Percentage Tinidazole in Different Brands of Antiprotozoal Tablets Contation Tinidazole Shiv Pratap Singh Dangi1 R.N. Shukla2 P.K. Sharma3 1Msc Student 2Professor & HOD 3Associated Professor 1,2,3Department of Applied Chemistry 1,2,3Samrat Ashok Technological Institute Vidisha (M.P.) 464001 [India] Abstract— Protozoal diseases particularly malaria, leishmaniasis and changes disease, are major cause of II. MATERIALS AND METHODS mortality in various tropical and subtropical regions. Where Antiprotozoal are drugs to treat infection cause by A. Collection of Samples: unicellular organisms that destroy protozoa or inhibit their I have collected four samples of different brands of growth and the ability to reproduce. Protozoal infection antiprotozoal tablets containing Tinidazole then desigenteted transmission can be person to person by infected water or as, TZ-1, TZ-2, TZ-3 and TZ-4. food, direct contact with a parasite, a mosquito or tick. B. Chemical and Reagents: Tinidazole is the most preferred choice of drug for intestinal amoebiasis. The aim of this study is to carry out the quality Methanol, Acetone, Dichloromethane and distilled water, all test of different brands of Tinidazole Tablets I analyzed solvents and reagents used were of analytical grade. various parameters such as identification, solubility and % assay to check the quality. All the tablets compared with III. METHODS authorized standard were found within the range. A. Description Key words: Tinidazole, Anti-protozoal, Amoebiasis, The description of each sample was performed as per the IP Protozoal disease, Anti-protozoal drug volume (III) 2007[10].
    [Show full text]
  • CRUX 71Sepoct2015
    VOLUME - XII ISSUE - LXXI SEP/OCT 2015 Amoebiasis, also known as amebiasis or entamobiasis, is an infection caused by any of the amoebas of the Entamoeba group. Symptoms are most common upon infection by Entamoeba histolytica. Amoebiasis can present with no, mild, or severe symptoms. Symptoms may include abdominal pain, mild diarrhoea, bloody diarrhea or severe colitis with tissue death and perforation. This last complication may cause peritonitis. People affected may develop anemia due to loss of 1 Editorial blood. Disease Invasion of the intestinal lining causes amoebic bloody diarrhea or amoebic colitis. If the parasite 2 reaches the bloodstream it can spread through the body, most frequently ending up in the liver Diagnosis where it causes amoebic liver abscesses. Liver abscesses can occur without previous diarrhea. Cysts of entamoeba can survive for up to a month in soil or for up to 45 minutes under fingernails. It 9 Trouble is important to differentiate between amoebiasis and bacterial colitis. The preferred diagnostic Shooting method it through faecal examination under microscope, but requires a skilled microscopist and may not be reliable when excluding infection. Increased white blood cell count is present in severe 10 Bouquet cases, but not in mild ones. The most accurate test is for antibodies in the blood, but it may remain positive following treatment. Prevention of amoebiasis is by separating food and water from faeces and by proper sanitation 11 Interpretation measures. There is no vaccine. There are two treatment options depending on the location of the infection. Amoebiasis in tissues is treated with either metronidazole, tinidazole, nitazoxanide, 12 Tulip News dehydroemetine or chloroquine, while luminal infection is treated with diloxanide furoate or iodoquinoline.
    [Show full text]
  • POISONS LIST APPENDIX Amoebicides: Carbarsone
    POISONS LIST APPENDIX Amoebicides: Carbarsone Clioquinol and other halogenated hydroxyquinoline compounds Dehydroemetine; its salts Diloxanide; its compounds Dimetridazole Emetine Ipronidazole Metronidazole Pentamidine; its salts Ronidazole Anaesthetics: Alphadolone acetate Alphaxolone Desflurane Disoprofol Enflurane Ethyl ether Etomidate; its salts Halothane Isoflurane Ketamine; its salts Local anaesthetics, the following: their salts; their homologues and analogues; their molecular compounds Amino-alcohols esterified with benzoic acid, phenylacetic acid, phenylpropionic acid, cinnamic acid or the derivatives of these acids; their salts Benzocaine Bupivacaine Butyl aminobenzoate Cinchocaine Diperodon Etidocaine Levobupivacaine Lignocaine Mepivacaine Orthocaine Oxethazaine Phenacaine Phenodianisyl Prilocaine Ropivacaine Phencyclidine; its salts Propanidid Sevoflurane Tiletamine; its salts Tribromoethanol Analeptics and Central Stimulants: Amiphenazole; its salts Amphetamine (DD) Bemegride Cathine Cathinone (DD) Dimethoxybromoamphetamine (DOB) (DD) 2, 5-Dimethoxyamphetamine (DMA) (DD) 2, 5-Dimethoxy-4-ethylamphetamine (DOET) (DD) Ethamivan N-Ethylamphetamine; its salts N-Ethyl MDA (DD) N-Hydroxy MDA (DD) Etryptamine (DD) Fencamfamine Fenetylline Lefetamine or SPA or (-)-1-dimethylamino-1, 2-diphenylethane Leptazol Lobelia, alkaloids of Meclofenoxate; its salts Methamphetamine (DD) Methcathinone (DD) 5-Methoxy-3, 4-methylenedioxyamphetamine (MMDA) (DD) Methylenedioxyamphetamine (MDA) (DD) 3, 4-Methylenedioxymetamphetamine (MDMA) (DD) Methylphenidate;
    [Show full text]
  • Short Reports Metronidazole in Treatment of Children with Amoebic Liver Abscess
    Arch Dis Child: first published as 10.1136/adc.48.11.911 on 1 November 1973. Downloaded from Short reports Archives of Disease in Childhood, 1973, 48, 911. Metronidazole in treatment of multiple abscesses which were not accessible by needle aspiration. All recovered but were given children with amoebic liver dehydroemetine during the postoperative period. abscess No relapses were observed during a 3-month follow-up. We have shown that metronidazole combined with dehydroemetine is an effective treatment of Discussion children with amoebic liver abscess and that the The results of this trial are similar to those former drug has advantages over chloroquine obtained in our previous study of metronidazole (Scragg and Powell, 1970). In adults, metro- combined with dehydroemetine in which 11 of 15 nidazole in the absence of other drug therapy is children were cured, 2 more required surgical extremely effective in curing amoebic liver abscess drainage, and 2 died (Scragg and Powell, 1970). and remains the best of the nitroimidazole We have indicated that age is a most important derivatives that we have investigated (Powell, 1972; factor in prognosis and that, regardless of the nature Powell and Elsdon-Dew, 1972). However, in the ofthe therapy, mortality is higher in infants and very very young we have been reluctant to abandon young children (Scragg and Powell, 1968). In the parenteral emetine preparations owing to the present study the average age of our patients was severity of the condition in this age group. Never- significantly lower than in our previous trials, hence theless, the highly satisfactory results that we have the efficacy of metronidazole alone was put to a obtained with metronidazole alone in hundreds of rigorous test.
    [Show full text]
  • Appendix I. Therapeutic Recommendations (Reprinted from the Medical Letter) the Medical Letter® on Drugs and Therapeutics
    Appendix I. Therapeutic Recommendations (Reprinted from The Medical Letter) The Medical Letter® On Drugs and Therapeutics Published by The Medical Letter, Inc .• 1000 Main Street, New Rochelle, NY. 10801 • A Nonprofit Publication Vol. 35 (Issue 911) December 10, 1993 DRUGS FOR PARASITIC INFECTIONS Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs, and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. The table below lists first-choice and alternative drugs for most parasitic infections. Adverse effects of antiparasitic drugs are listed on page 120. For information on the safety of antiparasitic drugs in pregnancy, see The Medical Letter Handbook of Antimicrobial Therapy, 1992, page 151. DRUGS FOR TREATMENT OF PARASITIC INFECTIONS Infection Drug Adult Dosage* Pediatric Dosage* AMEBIASIS (Entamoeba histolytica) a.ymptomatlc Drug of choice: lodoquinol' 650 mg tid x 20d 30-40 mg/kg/d in 3 doses x 20d OR Paromomycin 25-30 mg/kg/d in 3 doses x 7d 25-30 mg/kg/d in 3 doses x 7d Alternative: Diloxanide furoate' 500 mg tid x 10d 20 mg/kg/d in 3 doses x 10d mild to mod.rat. Int•• tlnal dl••••• Drugs of choice:3 Metronidazole 750 mg tid x 10d 35-50 mg/kg/d in 3 doses x 10d OR Tinidazole' 2 grams/d x 3d 50 mg/kg (max. 2 grams) qd x 3d s.v.r. Int•• tlnal dis.as. Drugs of choice:3 Metronidazole 750 mg tid x 10d 35-50 mg/kg/d in 3 doses x 10d OR Tinidazole' 600 mg bid x 5d 50 mg/kg (max.
    [Show full text]
  • Hepatic Amebiasis: Experience in the Therapy of 56 Cases*
    .4(1.4 AIH) l’ORJ.S,,pp/ 2. 303. 19111 HEPATIC AMEBIASIS: EXPERIENCE IN THE THERAPY OF 56 CASES* Ireneu Cruz and F. J. Z. Carneiro Chaves Serviço 2. Medicina. Hospital de Curry Cabral. Lisboa.Serviço de Terapêutica Médica (Medicina 11). Faculdade de Medicina. Hospital de S. João. Porto. SUMMARY The resulta of therapy in 56 consecutive cases of hepatic amebiasis are reviewed. In retrospecr, the resulta in patients receiving metronidazole alone, dehydroemetine combined with chioroquine, and dehydroemetine combined with chloroquine and metronidazole were compared. No deaths occured. Our resulta confirm the great efficacy of metronidazole alone. The response to treatment was similar in patients receiving dehydroemetine combined with chloroquine but the average number of days of hospitalization was greater in these patients. No advantage was demonstrated for rhe combination of metronidazole with dehydroe metine and chioroquine. In retrospect these patients proved to have a more severe and protracted course with more frequent surgical complications and a greater need for closed aspiration of the abscess. Closed aspiration, not used routinely, has not reduced the number of days of hospitaliza tion. Significant side effects were not observed. Arnebicidai drug therapy has dramatically changed the prognosis of hepatic ame biasis, nowadays a readily curable disease (Poweli, 1971). Enduring landmarks in the development of drug therapy were the introduction of emetine hydrochloride (Rodgers, 1912), foliowed by chloroquine (Conan, 1948) and later by metronidazole (Powell et ai, 1966). The efficacy of these drugs, in single or combined drug regimens has been weli proved (Powell, 1971; Adams and MacLeod, 1977). The purpose of the present study is to review in retrospect our experience with three drug regimens in 56 consecutive cases of hepatic amebiasis.
    [Show full text]
  • AMEBIASIS [Amebic Dysentery, Amebiosis]
    AMEBIASIS [Amebic Dysentery, Amebiosis] SPECIES: Nonhuman primates primary laboratory risk AGENT: Entamoeba histolytica. RESERVOIR AND INCIDENCE: The reservoir of E. histolytica is man. The infections is present worldwide but is most prevalent and severe in tropical areas, where rates may exceed 40% under conditions of crowding, poor sanitation, and poor nutrition. It is estimated that there are about 50 million case of invasive amebiasis and 40,000- 100,000 deaths annually worldwide. In temperate areas, however, amebiasis tends to be asymptomatic or a mild, chronic infection that often remains undiagnosed. In the USA, seropositive rates up to 2-5% have been reported in some populations. Reported incidence of 0-31% in the feces of clinically normal Rhesus monkeys, 2-67% in Chimps, and up to 30% in other NHP. TRANSMISSION: Transmission may be by ingestion of infective cysts, contaminated water or food, by flies, or fomites. Resistant cysts or more fragile trophozoites CYSTS are the INFECTIOUS form found in the stool of asymptomatic carriers or patients with mild disease. The cysts remain viable, if moist and cool for 12 days. They remain viable for 30 days in water. Laboratory animal personnel are usually infected from fecal matter transferred to the skin or clothing. DISEASE IN ANIMALS: In dogs, infection by E. histolytica is generally asymptomatic and frequently localized in the cecum. Occasionally, it can invade tissues and cause acute or chronic amebiasis. Rhesus monkeys are generally resistant and usually experience asymptomatic infection, but chronic, mild colitis can occur. In chimpanzees, the infection can persist for a long time, in most cases subclinically, but sometimes it invades the tissues causing ulcerative colitis and hepatic abscesses.
    [Show full text]
  • Cutaneous Amebiasis: 50 Years of Experience
    Cutaneous Amebiasis: 50 Years of Experience Jorge Fernández-Díez, MD; Mario Magaña, MD; Mario L. Magaña, MD Although cutaneous amebiasis (CA) is a rare of skin and subcutaneous tissues. Therefore, CA disease, it is a public health concern worldwide, is a particularly virulent form of amebiasis. particularly in developing nations. It gains impor- Cutis. 2012;90:310-314. tance because of its severe clinical course, which can be confused with other disorders. Therefore, knowledge of its clinical features, histopathology, utaneous amebiasis (CA) can be charac- and pathogenesis is essential. We present a retro- terized as injury to the skin and underly- spective analysis over 50 years of 26 patients with ing soft tissues by trophozoites of Entamoeba C 1,2 CA who were diagnosed and treated at 2 Mexican histolytica. Other species of the genus such as institutions. Our main focus was to draw clinical Entamoeba hartmanni, Entamoeba coli, Entamoeba information to identify mechanisms by which ame- gingivalis,3 and Entamoeba dispar4 are considered bae reach the skin, occurring in a relatively small nonpathogenic. Entamoeba dispar has now been rec- percentage of infected individuals. The recorded ognized as responsible for many cases of amebiasis data included age and sex ofCUTIS the patients, form of in patients who were previously considered “healthy presentation, any associated illnesses and/or fac- carriers.” It is morphologically indistinguishable from tors, and methods for diagnosis. Histologic slides E histolytica but genetically and serologically dif- were reviewed in all cases; cytologic preparations ferent.5,6 Entamoeba moshkovskii is morphologically also were available for 6 cases. Most patients indistinguishable from E histolytica and E dispar but were male (overall male to female ratio, 1.9 to 1).
    [Show full text]